A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1

Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma

(2010) Donna E. Hansel et al.   AMERICAN JOURNAL OF PATHOLOGY

The role of mTOR in bladder cancer

(2010) Kilian M. Gust et al.   CANCER BIOLOGY & THERAPY

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

(2010) K. Yu et al.   CANCER RESEARCH

Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome

(2010) David Lindgren et al.   CANCER RESEARCH

The Phosphoinositide 3-Kinase Regulatory Subunit p85  Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling

(2010) C. M. Taniguchi et al.   CANCER RESEARCH

Germline APC mutation spectrum derived from 863 genomic variations identified through a 15-year medical genetics service to French patients with FAP

(2010) A. Lagarde et al.   JOURNAL OF MEDICAL GENETICS

A method and server for predicting damaging missense mutations

(2010) Ivan A Adzhubei et al.   NATURE METHODS

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

(2010) Lucie C. Kompier et al.   PLoS One

Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation

(2009) Bijay S. Jaiswal et al.   CANCER CELL

mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice

(2009) Guiqin Hou et al.   CANCER LETTERS

Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer

(2009) C. M. Seager et al.   Cancer Prevention Research

Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer

(2009) F. M. Platt et al.   CLINICAL CANCER RESEARCH

PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

(2009) K. Kalinsky et al.   CLINICAL CANCER RESEARCH

Inactivation of p53 and Pten promotes invasive bladder cancer

(2009) A. M. Puzio-Kuter et al.   GENES & DEVELOPMENT

Activation of RAS Family Genes in Urothelial Carcinoma

(2009) I. Boulalas et al.   JOURNAL OF UROLOGY

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K

(2009) J M Askham et al.   ONCOGENE

A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression

(2008) Carolyn L. Buller et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

PTEN and the PI3-Kinase Pathway in Cancer

(2008) Nader Chalhoub et al.   Annual Review of Pathology-Mechanisms of Disease

Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity

(2008) Elena V Svirshchevskaya et al.   BMC CANCER

Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors

(2008) Markus Heidenblad et al.   BMC Medical Genomics

Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication

(2008) Efstathios Kastritis et al.   INTERNATIONAL JOURNAL OF CANCER

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.

(2008) Jorge A. Garcia et al.   MOLECULAR CANCER THERAPEUTICS

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE